Objective To evaluate the efficacy and safety of the irbesartan150mg（a new angiotesmⅡrecepˉtor antagonist）/hydrochlorothiazed12.5mg combination in patients with mild to moderate hypertension.Method The trial began with a2weeks single-blind lead-in periiod（perod A）followed by a8weeks double-blind therapy（period B），which were randomized.parallel group In period A the patients stopped taking the antihypertensive agents once taken.If their seated diastolic blood pressure（SeDBP）was90～110mmHg at the end of period A they would be put in two groups.And then51patients were randomized to irbesartan150mg/hydrochlorothiazed12.5mg combination and49patients were randomized to irbesartan150mg taking agents qd in period B.With dose of irbesartan300mg/hyˉdrochlorothiazed12.5mg combination or irbesartan300mg if the SeDBP≥85mmHg at4th week in period B all the daˉta were calculated with SPSS6.0.Results At end of the period B irbesartan/bydrochlorothiazed combination has reˉduced the seated systolic blood pressure（SeSBP）and SeDBP by additional23.6±11.5and15.8±8.5mmHg comˉpared with result of16.0±14.8and12.8±9.2mmHg of irbesartan monotherapy（P<0.001）;

导入期、恢复期、康复期三个治疗阶段的用量标准. ·. 使用效果参考表及说明.

艾滋病在线
lead-in period should be used...period during...